0
0
In a significant health policy development, the Indian government has announced the reduction of Goods and Services Tax (GST) on 33 life-saving cancer drugs and medicines for rare diseases from 12 percent to zero. This landmark move was declared by Union Finance Minister Nirmala Sitharaman following the 56th GST Council meeting held in early September 2025. Alongside this, the GST on three additional life-saving drugs used for cancer, rare diseases, and severe chronic illnesses was cut from 5 percent to zero. Meanwhile, the tax on many other medicines was reduced from 12 percent to 5 percent, marking a sweeping effort to improve the affordability of critical medications for millions of patients across India.
Key Developments and Context
This GST rationalization comes as part of a broader government initiative to simplify the tax structure on essential goods and healthcare products, announced by Prime Minister Narendra Modi in his Independence Day speech in August 2025. The GST Council’s recommendations aim to ease the financial burden on patients requiring long-term and expensive treatments, particularly for cancer and rare diseases, which often involve costly drug regimens.
Finance Minister Sitharaman stated at the press conference that exempting these 33 drugs and additional medicines from GST will make these life-saving treatments more accessible by lowering direct costs for patients and healthcare providers. Other medicines not falling into these exempt categories now attract a reduced GST rate of 5 percent, further encouraging affordability and compliance. These changes are set to take effect on September 22, 2025, coinciding with the Hindu festival of Navratri.
Contextualizing the GST Cuts
Previously, medicines in India faced multiple GST slabs of 5, 12, and 18 percent, depending on their classification. Many cancer and rare disease drugs fell under the 12 percent rate, increasing their cost burden. By slashing GST to zero on critical drugs, the government reduces taxation at one point of the supply chain, although manufacturers may still incur costs such as input taxes.
The GST Council retained a two-rate structure of 5 percent and 18 percent for most products and introduced a special 40 percent rate on “sin” and luxury goods. Medicines, medical devices, and consumables mostly come under the low GST bracket, now streamlined to 5 percent, except for the designated zero-rated life-saving drugs.
Public Health Implications
This policy shift is expected to have broad implications for public health in India. Cancer remains a leading cause of death nationally, with an estimated 1.4 million new cases and 800,000 deaths annually, according to the Indian Council of Medical Research (ICMR). Reduced drug costs can facilitate earlier and more consistent treatment, potentially improving survival rates and quality of life.
For rare diseases—which collectively affect an estimated 70 million Indians—cost-effective access to medicines is pivotal, given these conditions’ lifelong treatment needs and high drug prices.
Practical Implications for Patients and Healthcare Providers
For patients, these GST reductions mean tangible savings on drug prices, which could translate to better adherence and health outcomes. Hospitals and pharmacies may also pass on these savings, easing the economic burden on families.
Healthcare providers and pharmacists must stay informed about the new GST rates to ensure correct pricing and billing practices. Awareness campaigns could help disseminate information about these benefits to patients and caregivers.
Potential Limitations and Counterarguments
While the zero-GST move is widely positive, some taxation experts caution that complete exemption may have unintended effects on the pharmaceutical supply chain. Manufacturers cannot claim input tax credits (ITC) on GST paid for raw materials if medicines are fully exempted, potentially increasing production costs indirectly. This might offset some benefits unless balanced by other governmental incentives.
Moreover, ensuring that cost reductions reach patients directly requires robust regulatory oversight to prevent price markups or supply chain inefficiencies.
Conclusion
The reduction of GST on 33 cancer drugs and certain rare disease medicines to zero is an important milestone in India’s ongoing efforts to make healthcare more affordable and inclusive. By easing the tax burden on essential medicines, the government is taking steps to support patients facing chronic, costly conditions. While challenges remain in ensuring the intended benefits are fully realized, this fiscal policy change holds promise for improving access to lifesaving treatments for millions of Indians.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
